The log-rank test is frequently used to detect a potential treatment effect in randomized clinical trials with time-to-event endpoints. It is asymptotically the most powerful test under the proportional hazards setting, but it has been shown to markedly lose power when the proportional hazards assumption is violated [1] . Weighted log-rank tests with various fixed and adaptive weight functions have been proposed in the literature to increase the power of a trial when non-proportional hazards are expected e.g. [2] [3] [4] . In particular, the G ρ γ , family of weights proposed by Fleming and Harrington [5] allows the flexibility to assign greater weights to either early or late failure times as controlled by the two parameters, and one option to assign greater weights to late failure times is to set = ρ 0 and > γ 0. The most powerful weighted log-rank test assigns the weights proportionally to the magnitude of the log hazard ratio [1] .
was recently proposed in the Journal, which helps translate the weighted log-rank test to quantitative estimates that can facilitate the evaluation of a potential treatment effect in terms of its clinical meaningfulness [13] . We would like to encourage clinical trial practitioners to consider a weighted log-rank test when both the mechanism of action and existing clinical evidence point to a potential delayed treatment effect. With an appropriately chosen weight function the loss of power should be fairly minimal under the proportional hazards setting, and the gain in power can be substantial in the presence of non-proportional hazards. Even given the preference to follow the precedence of using the log-rank test in confirmatory trials, a weighted log-rank test may be pre-specified as an important sensitivity analysis to help better characterize the potential benefit of a new treatment.
